|
About the Confirmatory Testing category -Please read before posting
|
|
1
|
722
|
March 30, 2025
|
|
N-nitroso-Furosemide
|
|
4
|
665
|
July 6, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
5
|
258
|
July 6, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
11
|
4517
|
July 2, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
154
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
185
|
June 22, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
141
|
June 8, 2026
|
|
MS Method Development Criterias?
|
|
1
|
162
|
June 2, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
380
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
275
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
382
|
May 25, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
100
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2890
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
91
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
77
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
122
|
May 20, 2026
|
|
N Nitroso Tadalfil
|
|
14
|
1116
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1134
|
May 18, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
388
|
May 13, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
348
|
May 8, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
196
|
April 27, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
221
|
April 17, 2026
|
|
N-Nitroso meglumine
|
|
26
|
2469
|
April 8, 2026
|
|
MDD for cream formulation
|
|
0
|
108
|
April 3, 2026
|
|
Analysis method of cream
|
|
6
|
295
|
March 30, 2026
|
|
Optimized UHPLC–Derivatization Method for Low-Level Nitrite Detection in Pharmaceutical Excipients-Pub
|
|
0
|
226
|
March 23, 2026
|
|
How to Validate High-Resolution Mass Spectrometry for Nitrosamine Detection in Pharmaceuticals
|
|
3
|
379
|
March 21, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
349
|
March 19, 2026
|
|
Differences in Physical Form of Nitrosamine Reference Standards: USP vs. Other Suppliers
|
|
2
|
179
|
March 18, 2026
|
|
Scientific Clarification Request on Analytical Approach for Nitrosamine Determination in Quetiapine Oral Suspension
|
|
3
|
259
|
March 17, 2026
|